We are live on ! Find out more
BNGO icon

Bionano Genomics

142 hedge funds and large institutions have $121M invested in Bionano Genomics in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 29 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $4.27M | Put options by funds: $1.84M

72% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 29

21% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 19

1% more funds holding

Funds holding: 140142 (+2)

0.26% more ownership

Funds ownership: 27.55%27.81% (+0.26%)

18% less capital invested

Capital invested by funds: $146M → $121M (-$25.7M)

Holders
142
Holders Change
+2
Holders Change %
+1.43%
% of All Funds
2.28%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
50
Reduced
29
Closed
19
Calls
$4.27M
Puts
$1.84M
Net Calls
+$2.42M
Net Calls Change
-$1.07M

BNGO Hedge Fund Activity: Q4 2022 in Review

142 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q4 2022, worth a combined $121M — down 18% from $146M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new BNGO positions and 19 closed out — a net gain of 4 holders — while 50 added to existing stakes and 29 trimmed.

The largest buyer was BlackRock, adding an estimated $3.4M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $2.58M sold.

  • 142 institutional investors held Bionano Genomics (BNGO) as of Q4 2022, up from 140 in Q3 2022.
  • Funds reported $121M of Bionano Genomics stock for Q4 2022, down 18% quarter-over-quarter.
  • 23 funds opened new Bionano Genomics positions in Q4 2022 and 19 closed out, a net change of +4 holders.
  • The largest Bionano Genomics buyer in Q4 2022 was BlackRock, an estimated $3.4M added.
  • The largest Bionano Genomics seller in Q4 2022 was Renaissance Technologies, an estimated $2.58M sold.

Based on aggregated 13F filings for Q4 2022.